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Abstract
Background: Primary hepatic neuroendocrine tumors (PHNET) are extremely rare and difficult to distinguish from
primary and metastatic liver cancers since PHNETs blood supply comes from the liver artery. This study aims to
investigate CT and MR imaging findings of primary hepatic neuroendocrine tumor (PHNET) and correlation with
the 2010 WHO pathological classification.
Methods: We examined CT and MRI scans from 29 patients who were diagnosed with PHNET and correlated the
data with the 2010 WHO classification of neuroendocrine tumors.
Results: According to the 2010 WHO classification system, PHNETs are divided into three grades based on histological
criteria. Grade 1 tumors are singular, solid nodules with enhancement at the arterial phase on CT and MRI scans. In
grade 1 tumors, the dynamic-contrast enhancement curve shows rapid wash-in in the arterial phase. Grade 2 tumors
can have a singular or multiple distribution pattern, necrosis, and nodule or marginal ring-like enhancements.
Grade 3 tumors have multiple lesions, internal necrosis, and evidence of hemorrhage. Portal venous tumor
thrombus was seen in one case. As tumor grades increase, the capsule begins to lose integrity and tumor
apparent diffusion coefficient (ADC) values decrease(grade 1: 1.39 ± 0.20× 10−3 mm2/s versus grade 2: 1.26 ±
0.23× 10−3 mm2/s versus grade 3: 1.14 ± 0.17× 10−3 mm2/s).
Conclusion: CT and MRI can reflect tumor grade and pathological features of PHNETs, which are helpful in
accurately diagnosing PHNETs.
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Background
Neuroendocrine carcinoma (NEC) is rare and originates
in the gastrointestinal tract, neuroendocrine cells, and
pancreas. Although it resembles adenocarcinoma, well-
differentiated NEC behaves biologically in a more benign
fashion [1]. However, one report has shown that undiffer-
entiated NECs could possess invasive and metastatic char-
acteristics [2]. Primary hepatic neuroendocrine tumors
(PHNET) are rarer than NEC, grow slower, and have the
ability to become malignant. Only a minority of patients
have carcinoid syndrome. On CTand MRI scans, PHNETs
resemble hepatocellular-carcinoma (HCC), but patients
with PHNETs have a better prognosis. Despite tumor
recurrence, patients with carcinoid syndrome have a satis-
factory 5-year survival rate of 74–78 % and a 5-year recur-
rence rate of 18 % after a hepatectomy [2–5]. Since CT
and MRI scans are sensitive in finding primary liver le-
sions and metastases, these techniques could help clini-
cians identify suitable therapeutic approaches and further
improve the survival rate of patients.
However, there is some controversy surrounding
whether CT and MRI scans can predict tumor grade
and malignancy. One research group reported that the
CT features of hepatic neuroendocrine tumors vary
and do not correlate with their pathologic diagnoses
[6]. Another report found that well-differentiated pri-
mary neuroendocrine tumors resemble echinococcus
cysts on CT and MRI scans [7].
In this study, we retrospectively investigated 29 pa-
tients diagnosed with PHNET by surgery or puncture
and summarized the characteristics of CT and MRI
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scans as a way to improve the accurate of diagnosis of
PHNET. Additionally, we correlated our findings with




Between May 2004 and December 2013, 29 patients (13
males, 16 females; median age: 47.2 years of age) with
PHNETs were admitted to Beijing Chaoyang Hospital of
Capital University of Medical Sciences. Of these 29 pa-
tients, 5 cases had carcinoid syndrome, 7 patients experi-
enced pain in the right upper abdomen, 9 patients
complained of abdominal discomfort, PHNETs were iden-
tified in 6 patients by routine ultrasound, and 2 patients
had liver tumors detected by a chest CT exam. All patients
underwent a hepatectomy or an ultrasound- or CT-guided
liver puncture. PHNETs were confirmed by pathology and
immunohistochemistry. Serum levels of alpha-feto protei-
n(AFP) were normal (less than 40 ng/ml), viral hepatitis B
antigen was negative, and evidence of liver cirrhosis was
not observed.
All patients underwent CT and MRI scanning and pro-
vided written informed consent. The Hospital institu-
tional review board approved this study.
CT protocol for PHNETs
Abdominal helical CT examinations were performed with
multi-detector row scanners (Light Speed Ultra, GE
Healthcare, Milwaukee, Wis). Food and water were de-
prived 4–6 h before enhanced CT examinations. To show
contrast between the liver and digestive tract, an oral posi-
tive contrast agent (500 ml water combined with 10 ml
iopromide, Bayer Healthcare) was used. The patients were
in the supine position, scanning range was from the right
diaphragm to the kidney, slice thickness was 5 mm with
helical scan and the slice thickness of the reconstruction
image was 1.25 mm with a pitch of 0.984:1. All patients re-
ceived nonionic intravenous contrast material (Ultravist,
300mgI/ml, Bayer Technology & Engineering Company
Limited, Berlin, Germany), which was administered at a
rate of 4 mL/s (90–120 mL total dose) using a mechanical
power injector (Medrad, Pittsburgh, PA, USA) set at 230
mAs and 120 kVp. Thereafter, hepatic arterial, portal ven-
ous phase, and delayed phase images were acquired with
delays of 25 s, 50–60 s, and 2–3 min, respectively. The
slice thickness and reconstruction slice thickness were the
same with unenhanced CT. Multi-plane reconstruction
(MPR) images were obtained at ADW 4.2 workstation
(GE Healthcare, Milwaukee, Wis).
MRI protocol for PHNETs
Eighty-three percent of patients (24 out of 29) underwent
abdominal MRI examinations in a 3.0-T system with a
phased-array torso coil for signal reception (Magnetom
Trio, Siemens Medical Systems, Erlangen, Germany). A
respiratory-triggered T2-weighted fast spin-echo pulse se-
quence with fat-suppressed technique was performed. The
acquisition parameters were as follows: TR/TE (msec),
4000–5000/81; flip angle, 140°; field of view, 38 cm;
matrix, 256 × 256; number of sections, 30; section thick-
ness, 6 mm; interval; 1 mm; and one signal acquired. A
breath-hold T1-weighted fast low angle shot (FLASH)
GRE sequence was performed in all patients with a
chemical shift technique. The parameters were set as
TR/TE (msec), 210/2.45, 210/3.83; flip angle, 65°; field
of view, 38 cm; matrix, 256 × 256; number of sections,
30; section thickness, 6 mm; interval, 1 mm; and one
signal acquired. Three-Dimensional Volume Interpo-
lated Breath-hold Examination (3D-VIBE) was per-
formed during hepatic arterial, portal venous and
delayed phases at 25 s, 60–70 s and 2 min after ad-
ministration of a gadolinium-based contrast medium
(0.1 mmol/kg) at a rate of 3–5 mL/s, followed by a
saline flush (20 mL). The parameters were as follows:
TR/TE (msec), 3.68/1.22; Flip angle, 10°; field of view,
35 cm; matrix, 256 × 256; number of sections, 80; and
acquisition time, 21 s.
Diffusion-weighted MR imaging was performed before
dynamic imaging, using a single-shot spin-echo echo
planar imaging (EPI) sequence with b factors of 0 and
800 s/mm2 along the three orthogonal directions. The
sequence was obtained within two breath-holding pe-
riods for the whole liver. The parameters included: TR =
4000 ms, TE = 66 ms, matrix = 138 × 128, FOV = 32 to
38 cm adapted to individual body size, twenty-four slices
for each b factor for entire liver, thickness = 6 mm, inter-
slice gap = 0.6 mm, average = 2, bandwidth = 1735 Hz/
pixel, and acquisition time = 24 s for each breath-holding
period. The parallel imaging algorithms (GRAPPA) with
an acceleration factor of 2 were added. Spectral fat sat-
uration was employed systematically to suppress the
chemical-shift artifacts. ADC maps regarding isotropic
images were automatically acquired and all mean ADCs
of the lesions were measured on those maps. For pa-
tients who did not hold their breath within 24 s, we in-
duced slices for each b factor and added the thickness
of the slice and the gap. The acquisition time in scan-
ning the whole liver for hold-breath one time could be
reduced to 16 s.
Data analyses
Two radiologists blindly analyzed dynamic-contrast en-
hancement curves (arterial and portal phases) and liver
lesions on unenhanced and post-enhanced CT and MRI
scans. Measurements of attenuation avoided cystic,
necrotic and hemorrhagic areas. If tumors were cystic
or predominantly cystic, regions of interest (ROI) on
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unenhanced and post-enhanced CT and MRI scans
were placed in the solid area or margins. Regions of
interest (ROI) on diffusion-weighted images were
carefully identified in the margins or solid area and
ADC values were recorded. Experienced pathologists
evaluated hematoxylin-eosin (HE) slides and PHNET
grades were defined according to the 2010 WHO classifi-
cation of gastrointestinal neuroendocrine tumors.
Grade 1(G1): the mitotic rate was < 2 per 10 high
power field and the Ki-67 index was ≤ 2 %. Grade 2(G2):
the mitotic rate was 2–20 per 10 high power field, and
the Ki-67 index was 3–20 %. Grade 3 (G3): the mitotic
rate was >20 per 10 high power field and the Ki-67
index > 20 %
Results
Using pathology and the 2010 WHO classification of
PHNET, eight cases were defined as G1, 10 cases were
defined G2, and 11 cases were defined G3.
All 19 singular lesions (G1 8 cases, G2 7 cases and G3
4 cases) underwent surgical resection. The maximum
diameter of the mass was 8 cm with a clear border.
Twelve lesions were predominantly solid, one case
showed calcification, and the remaining 6 cases were
cystic-solid or predominantly cystic.
HE staining of G1 lesions revealed well-differentiated
round or ovoid cells arranged in nests and glandular
duct or chrysanthemum formation. The mitosis rate
ranged from 0 to 2 per 10 high power fields. In G2 le-
sions, the cell arrangements were irregular, with mild
differentiation and minimal nuclei atypia. The mean mi-
tosis rate was 10 (range: 4 to 16) per 10 high power field.
G3 lesions were poorly differentiated with large nuclei
and the mean mitosis rate was 27 (range: 22 to 40) per
10 high power field.
Histology showed positive staining for the neuroendo-
crine marker, synaptophysin (Syn) and CT imaging re-
vealed singular lesions (8 cm) with clear borders and
irregular margins. We found multiple liver lesions of dif-
ferent sizes. One PHNET case progressed to tumor
thrombus in the portal vein with no evidence of liver cir-
rhosis in the surrounding normal tissue.
Based on CT imaging (Table 1) and MRI data (Table 2),
all G1 liver lesions were singular with only one lesion lo-
cated in left lobe and remaining lesions the in right lobe.
A CT scan of one patient revealed central necrosis in the
absence of hemorrhage and cystic change. One patient
had calcification and mild enhancement. For the other 6
patients, pre- and post-enhanced CT densities were
homogenous and showed marked enhancement (Fig. 1),
while the dynamic-contrast enhancement curves of
seven lesions (87.5 %) appeared as type III. All lesions
showed enhanced capsules in the delayed phase of post-
enhancement CT while one lesion appeared plateau-like
type. Seven out of eight patients with G1 PHNETs
underwent a MRI examination in addition to a CT scan
(Table 2). The lesions showed hypointensity on pre-
enhanced T1-weighted and homogeneous, mildly high
intensity or high intensity on T2-weighted imaging. En-
hancements on post-enhanced MRI scans had markedly
high (6 cases) and mildly high intensities (1 case). The
ADC values in the liver tumors were lower than the sur-
rounding normal liver tissue (1.39 ± 0.20 × 10−3 mm2/s
versus (2.0 ± 0.38 × 10−3 mm2/s). All lesions showed en-
hanced capsules in the delayed phase of post-enhancement
MRI scans. These data further confirm that G1 lesions were
benign or low-grade malignant tumors and distinguishable
from hepato-cellular carcinoma.
For the ten patients with G2 PHNETs, CT scans re-
vealed both single and multiple lesions with necrosis
(Table 1). Nodular or marginal-ring enhancements were
presented on post-enhanced CT images (Fig. 2). Seven
out of ten patients had single lesions that appeared with
capsule-enhancement in the delayed phase. One case ap-
peared as cystic and solid and was presumed to be echi-
nococcosis on unenhanced, post-enhanced CT imaging
Table 1 CT appearance of PHNET
Pathological
grade
Case Lesion Location Unenhanced CT Contrast-enhanced series (attenuation) Type of dynamic
enhanced curvesb









Hyper Iso Hyper Iso
G1 8 8 0 7 1 7 1 6 2 7 1 8 0 8 0 1 7
G2 10 7 3 6 1 10 0 4 6 8 2 8 2 9 1 1 9
G3 11 4 7 2 2 10 1 0 11 9 2 11 0 9 2 1 11
aIf the tumor showed a cystic or predominantly cystic appearance, the attenuation of contrast-enhanced series on arterial phase, portal phase and delayed phase were
measured in the margin region. The type of dynamic enhanced curves were obtained from the margin or solid content
bType I dynamic enhancement curves show lesions with gradual enhancements and peak enhancements in the delayed phase. Type II dynamic enhancement
curves show lesions with peak enhancements at the arterial phase and no decrease at the portal phase or delayed phase. Type III curves shows lesions with peak
enhancements at the arterial phase and a slight decrease at the portal phase and the delayed phase
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and a pre-operational ultrasound because the patient
lived in an area with an echinococcosis epidemic. This
case was later confirmed to be a G2 PHNET based on
pathology following surgical resection. Three cases had
multiple lesions and were misdiagnosed as metastases
on CT and MRI scans, but were later determined to be
G2 PHNETs based on needle biopsies. Furthermore,
MRI revealed necrosis and cystic change in these lesions.
Signal intensities were heterogeneous on T1- and T2-
weighted imaging with significant necrosis (Fig. 2) and
appeared as hypointensity on T1WI and mildly high
intentsity on T2WI. The ADC values on diffusion-
weighted imaging (DWI) were lower relative to normal
liver tissue (1.26 ± 0.23 × 10−3 mm2/s versus 2.02 ± 0.26 ×
10−3 mm2/s, respectively). Nodular or marginal-ring en-
hancements were presented on post-enhanced MR images.
Dynamic enhanced curves (9/10) with CT and MRI ap-
peared as type III in the tumor margin or solid area.
Four out of eleven cases with G3 PHNETs were singu-
lar and the remaining seven cases appeared as diffuse,
multi-nodular or marginal-ring enhancement on CT.
Three multi-nodular cases were misdiagnosed as metas-
tases and two cases were misdiagnosed as hepatocellular
carcinoma with diffuse intra-liver metastases. This mis-
diagnosis further suggests that a combination of a de-
tailed clinical history and lab tests are essential in the
Table 2 MR appearances of PHNET
Pathological
grade











Marked Mild Type II Type III
G1 7 7 0 6 1 7 5 1 6 1 1 6 1.39 ± 0.20
G2 8 6 2 5 1 8 7 1 8 0 0 8 1.26 ± 0.23
G3 9 4 5 2 2 9 3 6 9 0 0 9 1.14 ± 0.17
aType I dynamic enhancement curves show lesions with gradual enhancements and peak enhancements in the delayed phase. Type II dynamic enhancement
curves show lesions with peak enhancements at the arterial phase and no decrease at the portal phase or delayed phase. Type III curves shows lesions with peak
enhancements at the arterial phase and a slight decrease at the portal phase and the delayed phase
Fig. 1 CT scan and histology of grade 1 PHNET. Post-contrast CT image of the arterial phase (a), the portal venous phase (b) and the delayed phase (c)
shows marked enhancement in the PHNET relative to the liver parenchyma (right lobe at the arterial phase), and slight hyperattenuation relative to the
surrounding liver parenchyma in the delayed phases. The integrity of the capsule is maintained. The mitosis rate shows up as hypo-density and no
enhancement on the dynamic enhanced CT scan. HE staining of the tumor (d) shows tumor cells arranged as solid nests, consistent cell size and mitosis
rate was 1/10 HPF. Magnification: D = 100X
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accurate diagnosis of PHNET. The dynamic-contrast en-
hancement curves illustrated type III. Hemorrhage was
seen in one tumor (Fig. 3) with no evidence of lymph
node metastases. However, one case had tumor
thrombus in the portal vein in and 10 cases had necro-
sis, heterogeneous hypo-intensity on T1WI and high in-
tensity or mildly high intensity on T2WI as illustrated
by MRI. On T2WI, one case showed the liquid-liquid
level and another showed hypo-intensity in the lower
part. All patients (9/9) showed multi-nodular or
marginal-ring markedly high enhancements on post-
enhanced MRI and at the margins or solid area of the
tumor dynamic-contrast enhancement curves (type III).
ADC values were lower in liver lesions compared to the
surrounding normal liver tissue (1.14 ± 0.17 × 10
−3 mm2/s versus 1.97 ± 0.30 × 10−3 mm2/s, respectively).
In one case, tumor thrombus appeared as a filling-
defect in the portal vein.
Discussion
In this work, we found that careful imaging with CT and
MRI scans could accurately reflect the histological features
of primary hepatic neuroendocrine tumors (PHNETs) and
increase the likelihood of a correct diagnosis. A tumor
that originates from neuroendocrine cells is a neuroendo-
crine tumor (NET). There are two types of NETs: neural
neuroendocrine tumors and epithelial neuroendocrine tu-
mors. Primary hepatic neuroendocrine tumors (PHNETs)
Fig. 2 CT scan and histology of grade PHNET. Post-contrast CT image of the arterial phase (a), portal venous phase (b), and delayed phase (c).
The PHNET (5.4 × 5.7 cm in size) has marginal ring-like and septal enhancements (right lobe). Arterial phases reveal a wash-in pattern at the periphery
of the tumor. Portal phase and delayed phase reveal slight peripheral hyper-attenuation compared with the surrounding liver parenchyma. HE staining
shows liver tumor cells arranged in an island. Atypia and nucleoli were not readily apparent but nuclear chromatins were distributed in fine granules
(d). Mitosis rate was 2–3/10 HPF and blood sinus was abundant in the intestinal with no hemorrhage
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develop in the intrahepatic bile duct epithelium and have
an extremely low incidence of 0.17 % [8].
G1 and G2 NETs are low grade neoplasms and have a
good prognosis. Neuroendocrine carcinomas (NECs) are
G3 neoplasms that are structurally similar to NETs. The
neuroendocrine markers synaptophysin (Syn) and chro-
mogranin A (CgA) are diffusely expressed and accom-
panied by nuclear atypia, focal necrosis, and a high
mitosis rate (>20/10 HPF).
Hepatic NECs have a better prognosis than hepatocel-
lular carcinoma [9], but characteristic local invasion,
metastases, and serious complications of carcinoid syn-
drome contribute to the poor outcome of patients with
hepatocellular carcinoma [10–12]. Furthermore, positive
staining for chromaffin granule (CgA), synaptophysin
(Syn), and neuron specific enolase (NSE) are important
in the pathological diagnosis of PHNET.
Zhu Z et al. [13] reported that PHNETs appear as a
single tumor. Our MRI and CT scans revealed that G1
PHNETs usually have single lesions in the right lobe
whereas G3 PHNETs commonly have multiple diffuse
lesions or one large tumor accompanied by several satel-
lite lesions. PHNETs are difficult to distinguish from
liver cancer [14]. Kim JE et al. [6] reported variation in
the CT images of hepatic neuroendocrine tumors that
did not correlate with their pathologic diagnoses. In
these cases, PHNETs showed arterial enhancements that
resembled hepatocellular carcinoma and delayed phase
enhancements that resembled a cholangiocarcinoma. In
our study, we had six cases of PHNETs (three cases were
G2 and three cases were G3) that were misdiagnosed as
metastases. After analyzing the rationale behind the
misdiagnosis, we found that PHNETS are markedly en-
hanced on the arterial phase and portal phase, which
commonly shows a major lesion surrounded by several
satellite nodules. Furthermore, the major lesion usually
has discontinuous and irregular capsule-enhancements.
ADC values showed that the PHNET had restricted dif-
fusion compared with the surrounding normal liver, which
confirmed that the PHNET was malignant. As PHNET le-
sions grew in size, the number of intrahepatic lesions in-
creased from single to multiple, focal hemorrhage,
necrosis, and portal venous thrombosis became prevalent
[15]. Su M et al., [16] analyzed six cases of PHNET with
multiple lesions. These tumors appeared as nodular or
ring-like enhancements that suggest that PHNET is not of
a multifocal origin, which is common to liver cancer.
A rich blood supply from the hepatic artery is one
characteristic of PHNETs, which is reflected in the type
of dynamic enhancement curves. In our study all lesions
were markedly enhanced in the arterial phase and the
reconstruction of the arterial phase confirmed a rich
blood-supply. However, it is difficult to distinguish
PHNETs from other diseases such as primary hepatocellu-
lar carcinoma (HCC), hepatic adenoma and focal nodular
hyperplasia (FNH), hepatic epithelial angiomyolipoma and
liver metastases, which also receive their blood supply the
liver artery. Primary hepatocellular carcinoma (HCC) has
the typical manifestations of marked arterial enhancement
and shows a washout pattern that makes it easy to mis-
diagnose PHNET with tumor thrombus as HCC. The ma-
jority of HCC patients has a history of hepatitis, liver
cirrhosis, and increased serum levels of alpha-feto protein
(AFP). In contrast, PHNETs show a washout in portal
Fig. 3 MRI and histology of grade 3 PHNET. Transverse T1-weighted (a), transverse T2-weighted (b), contrast-enhanced dynamic T1-weighted at
the arterial phase (c) and delayed phase (d). Figure e and f illustrate liver arterial reconstruction, and transverse diffusion-weighted imaging(b = 800 s/mm2,
respectively). This grade 3 tumor (8.4 cm in size) was located in the right lobe with a cystic change in the liver wall. Multiple satellite nodules show
marked peripheral enhancement in the arterial phase and slight hyper-intensity relative to the surrounding liver parenchyma in the delayed phase.
Diffusion-weighted imaging (Figure f) shows high peripheral signal intensity, which reflects the diffuse restriction of water. Figure e confirms that the
tumor blood supply comes from the liver artery. HE staining of liver tumor cells with atypia, varying sizes, multiple mitosis rates, and irregular nucleoli (g).
Staining for the neuroendocrine marker, synaptophysin (Syn) was positive (h). Magnifications: G and H = 100X
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venous phase and higher enhancements in delayed phases
compared to the surrounding liver parenchyma. Hepatitis,
liver cirrhosis, portal vein thrombosis, and increased
serum AFP levels are uncommon in PHNET patients.
Hepatic adenoma and focal nodular hyperplasia (FNH)
has a portal venous phase enhancement that is equal to
or slightly higher than normal liver tissue. Hemorrhage
and necrosis are rarely seen in FNH. Individuals who
have a history of taking oral contraceptives have a
higher incidence of hepatic adenomas [17]. According
to Burke C et al., [18] liver-specific contrast agents
could be used to distinguish FNH from PHNETs. Chem-
ical shift imaging could be used to differentiate PHNETs
from hepatic adenoma based on fat content since aden-
omas have specific appearances on in-phase and out-of
phase T1WI, which have markedly suppressed signal in-
tensities on the out-of phase T1WI FLASH sequence.
Liver metastases have a rich blood supply as well, but
the characteristic bull’s eye pattern on MRI and CT
scans distinguish liver metastases from PHNETs.
One limitation of our study is the small sample size,
which results from the low incidence of this rare tumor.
Therefore, future studies must include more cases,
which will allow for the inclusion of statistical data.
Conclusion
In conclusion, the appearances of CT and MRI reflect
the biologically benign fashion of G1 and G2 PHNETs
and the malignant growth of G3 PHNETs. This data
could be used to diagnose PHNETS and distinguish
grade 1 and 2 tumors from grade 3 tumors, which typic-
ally show multiplicity and central necrosis.
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